Release
2025/03/03
OSAKA, Japan, March 3, 2025 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") is pleased to announce the conclusion of a comprehensive collaboration agreement (hereinafter "this Agreement") with Osaka Metropolitan University (Osaka Prefecture; President: Masahiro Tatsumisago) concerning "Information, Research Technology, and Human Resource Development in the Field of Infectious Diseases." The agreement aims to contribute to the improvement of public health and the maintenance and promotion of people's health in Osaka Prefecture and beyond, both domestically and internationally.
Shionogi and Osaka Metropolitan University have been advancing initiatives such as "the development of next-generation diagnostic technologies for acute respiratory infections and the collection of clinical specimens for this purpose" and "the establishment of a clinical research network" by leveraging their common research and development needs in the field of infectious diseases and their shared advantage of being based in Osaka Prefecture. In light of the experiences gained from the COVID-19 pandemic, Osaka Metropolitan University, which possesses a broad range of academic disciplines, has established an "Administrative Collaboration Division" to conduct infectious disease countermeasure research from a macro-infectious disease science perspective in collaboration with government agencies through the Osaka International Research Center for Infectious Diseases（OIRCID）. This initiative aligns with Shionogi's ability to drive innovation centered on new drug development. Both parties share a common goal of advancing the field of infectious diseases, strengthening public health systems in Osaka Prefecture and Osaka City, and delivering tangible benefits to society, leading to the conclusion of this Agreement.
Under this Agreement, Shionogi and Osaka Metropolitan University will undertake the following initiatives:
1. Education, research, awareness activities, information gathering, and dissemination from an international perspective.
2. Strengthening the public health system.
3. Preparedness and response measures for infectious disease crises.
4. Policy support or recommendations directly linked to Osaka Prefecture or Osaka City regarding infectious disease countermeasures.
5. Exchange and development of researchers and students.
6. Other initiatives that contribute to the objectives of this Agreement.
Through this Agreement, Shionogi and Osaka Metropolitan University will continue to promote effective prevention, preparedness, and response measures for potential future pandemics. By establishing the 'Osaka Model' through industry-government-academia collaboration, we aim to contribute to improving public health in Osaka Prefecture and beyond, as well as to maintaining and enhancing people’s health.
About Shionogi & Co., Ltd.
For over 60 years, Shionogi has been engaged in the research and development of infectious disease treatments. Identifying " Protect people from the threat of infectious diseases" as a material issue (materiality) to be addressed, the company is working towards the realization of comprehensive infectious disease care. As a leading company in the field of infectious diseases, Shionogi is strengthening its initiatives, including collaborations with external partners, to provide healthcare solutions to a broader audience and continuously address a wide range of infectious diseases.
About Osaka Metropolitan University
Osaka Metropolitan University serves as a "knowledge hub" that contributes to regional development and the resolution of global challenges by integrating the expertise of its 15 graduate schools to create new value through "comprehensive knowledge." In response to requests from Osaka Prefecture and Osaka City, the university established the " Osaka International Research Center for Infectious Diseases（OIRCID）" in February 2023 to serve as a hub for infectious disease countermeasures in Osaka. With a vision of "creating a city resilient to infectious diseases in the international city of Osaka," the center implements "comprehensive knowledge" and conducts research from a macro-infectious disease science perspective.
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html